It was the first time that Group Leader and ICREA researcher Maria Macias organised a Barcelona BioMed Conference, in collaboration with the BBVA Foundation, held on 28-30 November 2016. When asked about the experience, she highlights that having been able to draw together experts from very diverse research fields and backgrounds was “extremely fulfilling” for her. The conference programme covered areas spanning genomics to systems biology, cellular structural biology, big data, and patients-focussed approaches.
International experts in structural biology, such as Nobel laureate Ada E. Yonath, and in massive genomic analysis, such as the bioinformatician Chris Sander—one of the fathers of biocomputation—, are gathering in Barcelona this week with the aim to identify synergies and throw light on the jumble of massive biological data currently available.
The Barcelona Biomed Conference organised by IRB Barcelona and the BBVA Foundation will be held from today 28 to 30 November at the Institut d’Estudis Catalans.
This afternoon, there will be an open debate on “Women in science”, chaired by Ada E. Yonath.
The third video of IRB Barcelona’s series “Meet Our Scientists” is devoted to ICREA researcher Maria Macias, who describes her field as “exciting and understandable”.
Her research focuses on determining protein structures that have the potential to improve drug development
Maria Macias, Pau Martín, and Joan Massagué publish a featured review article in Trends in Biochemical Sciences (TIBS) on the Smad protein family, the members of which play a key role in cancer.
The article is accompanied by a web application in which available 3D structures of Smads can be explored, as can their alterations in several metazoa, their variability in humans, and their mutations in tumours.
Feature article on the work being performed by María Macias and Antoni Riera at IRB Barcelona on the hormone somatostatin and that has been published in Ang. Chemie.
Read the festure article Madri+d (PDF in Spanish)
Read the article online at...
For several decades the pharmaceutical industry has been interested in achieving peptide analogues —similar molecules with improved properties— of the natural hormone somatostatin. This hormone and another two analogue compounds, octreotide and lanreotide, are used for the treatment of several kinds of neoplasia, such cancer of the thyroid, pancreas and prostate, in diseases associated with the growth hormone, for example in gigantism, and in digestive hemorrhages. Headed by...
Several national and international media, such as Science Daily, have reported on the latest findings by Maria Macias, at IRB Barcelona, and Joan Massagué, adjunct director at IRB Barcelona and researcher at the Memorial Sloan-Kettering Cancer Center. After three years of intensive work, the team of researchers have characterized the life cycle of Smad proteins, essential components in the modulation of cell cycle. These results may prove crucial to develop new clinical therapies against cancer.
Scientists at Memorial Sloan-Kettering Cancer Center in New York and at IRB Barcelona reveal the mechanism of action of a protein that is essential for life and is associated with disease.
The consortium involves the research group headed by María J. Macías, specialist in the determination of biomolecular structures.
Unless you are a molecular biologist, you may not have heard the term ubiquitin. Given its essential role in the cell, however, it is likely that its protagonism and popularity will increase. One of the processes in which ubiquitin plays a relevant role is in the degradation of proteins. In the cell, the generation of proteins is just as important as their destruction, as well as the maintenance of a correct balance between both processes.
Proteins become candidates for degradation when they are defective, when they have completed their function and are no longer necessary, or when they belong to pathogenic organisms. Ubiquitin attaches itself to these proteins as if it were an...